FAPI-PET predicts treatment response in patients with rheumatoid arthritis
In this study, they further analyzed data from 19 patients to determine whether FAPI-PET could help predict treatment responses.
All of the patients had high or moderate disease activity and underwent PET/CT exams at baseline, as well as standard F-18 FDG PET/CT scans for comparison. Subsequent treatments included conventional DMARDs (including methotrexate, leflunomide, cyclophosphamide, and tripterygium wilfordii), and synthetic DMARDs (including etanercept, adalimumab, and Janus Kinase inhibitors). Six patients received additional prednisone, and six patients had nonsteroidal anti-inflammatory drugs.Representative Ga-6...
Source: AuntMinnie.com Headlines - January 9, 2024 Category: Radiology Authors: Will Morton Tags: Subspecialties Nuclear Radiology Source Type: news
Intas in pact with Spanish drug maker mAbxience to sell biosimilar etanercept in over 150 countries
mAbxience, a majority-owned company of German drug maker Fresenius Kabi, also has partial ownership from Insud Pharma, will be responsible for the development, manufacturing, and supply of the Etanercept biosimilar. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 22, 2023 Category: Pharmaceuticals Source Type: news
Drugmakers opt in to Medicare drug price negotiations
A pharmacist holds a bottle of the drug Eliquis, made by Pfizer Pharmaceuticals, at a pharmacy in Provo, Utah, January 9, 2020. All drugmakers of the first 10 medicines selected for Medicare drug price negotiations have agreed to participate in the talks, even after many of them sued to halt the…#eliquis #provo #utah #medicare #jardiance #boehringeringelheim #xarelto #januvia #farxiga #enbrel (Source: Reuters: Health)
Source: Reuters: Health - October 2, 2023 Category: Consumer Health News Source Type: news
Here Are the First 10 Drugs Biden Will Target for Price Negotiations
WASHINGTON (AP) — The popular diabetes treatment Jardiance and the blood thinner Eliquis are among the first drugs that will be targeted for price negotiations in effort to cut Medicare costs.
President Joe Biden’s administration on Tuesday released a list of 10 drugs for which the federal government will take a first-ever step: negotiating drug prices directly with the manufacturer.
[time-brightcove not-tgx=”true”]
The move is expected to cut costs for some patients but faces litigation from the drugmakers and heavy criticism from Republican lawmakers. It’s also a centerpiece of t...
Source: TIME: Health - August 29, 2023 Category: Consumer Health News Authors: TOM MURPHY, AMANDA SEITZ and CHRIS MEGERIAN / AP Tags: Uncategorized wire Source Type: news
Colorado will consider capping the price of these 5 widely prescribed drugs
Colorado’s new Prescription Drug Affordability Board has identified five costly medications used to treat autoimmune diseases, HIV and cystic fibrosis that could receive state-mandated price ceilings — but it’s not clear how that will affect patients. The board was created by a 2021 law that…#colorado #genvoya #enbrel #cosentyx #crohn #trikafta #lilacummings #cummings #coloradoinsurance #michaelconway (Source: Reuters: Health)
Source: Reuters: Health - August 14, 2023 Category: Consumer Health News Source Type: news
Pediatric Psoriasis: Infection Risk Low With Systemic Meds Pediatric Psoriasis: Infection Risk Low With Systemic Meds
The results are from a large cohort study that estimated the 6-month rate of infections among children with psoriasis who started treatment with ustekinumab, etanercept, or methotrexate.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 16, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal
Dec 12 (Reuters) - Amgen Inc (AMGN.O) on Monday agreed to buy Horizon Therapeutics Plc (HZNP.O) in a deal valued at $27.8 billion, fortifying its rare diseases portfolio in the biggest buyout in the sector this year. The company will pay $116.50 in cash, a premium of nearly 20% to the stock's last…#refinitiv #chemocentryxinc #medicare #williamblair #bankofamerica #horizontherapeuticsplc #trimbleinc #coupasoftwareinc #coupasoftware #enbrel (Source: Reuters: Health)
Source: Reuters: Health - December 13, 2022 Category: Consumer Health News Source Type: news
Combined Use of Anakinra, Etanercept, and BETA-2 Score Linked With Improved Islet Cell Transplant Outcomes Combined Use of Anakinra, Etanercept, and BETA-2 Score Linked With Improved Islet Cell Transplant Outcomes
In a single center ' s 20-year experience, patients with sustained graft survival were more likely to have had combination treatment with anakinra plus etanercept and a BETA-2 score of 15 or higher within 1 year, researchers say.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 26, 2022 Category: Transplant Surgery Tags: Diabetes & Endocrinology News Source Type: news
Janssen Initiates First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care for People of Color with Moderate to Severe Plaque Psoriasis
HORSHAM, PENNSYLVANIA, March 22, 2022 – Psoriasis (PsO) can take a physical, psychological, and emotional toll on the more than 8 million Americans living with the disease; and for people of color, there are additional challenges due to limited medical research and education, as well as underrepresentation in clinical studies.1,2,3 This has led to a lack of data and barriers to optimal care for diverse patient populations.2 PsO may also present with less noticeable skin reddening on darker skin tones, which can make it harder for healthcare providers to identify and lead to misdiagnoses in people of color. To help addres...
Source: Johnson and Johnson - March 23, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus placeb...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Certain Biologics May Boost Infection Risk in Psoriasis Patients Certain Biologics May Boost Infection Risk in Psoriasis Patients
Psoriasis patients who are new users of infliximab and adalimumab appear to be at a greater risk of serious infection than those beginning therapy with etanercept, according to French researchers.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 2, 2021 Category: Infectious Diseases Tags: Dermatology News Source Type: news
New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more diffic...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Etanercept May Not Help Some With Suspected Nonradiographic-axSpA Etanercept May Not Help Some With Suspected Nonradiographic-axSpA
Treatment with etanercept does not appear to yield significant clinical improvement in patients suspected of having nonradiographic axial spondyloarthritis, research suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 17, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news
RA Remission? Stop Methotrexate, Keep Etanercept RA Remission? Stop Methotrexate, Keep Etanercept
In patients with RA whose disease is well controlled by methotrexate and etanercept, withdrawal of methotrexate led to long-term outcomes that were nearly as good as continuation of combination therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 24, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news
The Risk of Uveitis in JIA Patients Receiving Etanercept The Risk of Uveitis in JIA Patients Receiving Etanercept
Uveitis is a known complication of juvenile idiopathic arthritis. How might the use of etanercept impact the risk for developing this condition?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 19, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
